Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: majormember who wrote (603)	6/16/1998 2:50:00 PM
From: Jim Mac	Read Replies (1) \| Respond to of 1754

VISX will likely be at $75 this year, and $100 - $150 next year, based on earnings/growth, barring any market/industry problems. SNRS--who knows? SNRS won't get FDA approval until late 1999 or 2000. They'll burn all their cash by then, and have to raise more for production and placement. Granted, when they do start placing systems within 2 years, they'll be entering a thriving market, and should hit the ground running, leading to a rapid ramp of revs/earnings. But that's still a long way off, and enthusiasm for such embryonic companies may decline if the Asian situation starts to affect U.S. sentiment toward holding stocks. I like SNRS, but at a lower price. And after it hits Nasdaq.